{"id":559031,"date":"2021-08-23T10:56:02","date_gmt":"2021-08-23T10:56:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=559031"},"modified":"2021-08-23T10:56:02","modified_gmt":"2021-08-23T10:56:02","slug":"eosinophilic-esophagitis-market-insight-epidemiology-and-market-forecast-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/eosinophilic-esophagitis-market-insight-epidemiology-and-market-forecast-2030_559031.html","title":{"rendered":"Eosinophilic Esophagitis Market Insight, Epidemiology And Market Forecast -2030"},"content":{"rendered":"
\n
\"Eosinophilic<\/a><\/div>\n
\n
DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u2018Eosinophilic Esophagitis Market\u2019 report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of EoE in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.<\/div>\n

Eosinophilic Esophagitis Market Insight, Epidemiology and Market Forecast -2030<\/strong><\/p>\n

Eosinophilic Esophagitis Market<\/strong><\/p>\n

The EoE market report<\/a> provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted EoE market Size from 2018 to 2030, segmented by seven major markets. The report also covers the current EoE treatment practice\/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying market potential.<\/p>\n

Eosinophilic Esophagitis Market Outlook<\/strong><\/p>\n

The Eosinophilic Esophagitis market outlook<\/a> of the report builds a detailed comprehension of the historical, current, and forecasted EoE market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.<\/p>\n

This segment gives a thorough detail of Eosinophilic Esophagitis market trend<\/a> of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.<\/p>\n

According to DelveInsight, the Eosinophilic Esophagitis market in the 7MM is expected to change in the study period 2018–2030.<\/p>\n

Currently, the 3 “D”s (“Drugs, Diet, and Dilation”) are considered the fundamental components of treatment. The first two components, which involve the use of proton pump inhibitors, corticosteroids, immunosuppressants, and empirical diets or guided food elimination based on allergy tests, are more useful in the initial phases, whereas endoscopic dilation is reserved for esophageal strictures. Herein, the most important aspects of eosinophilic Esophagitis pathophysiology will be reviewed, in addition to evidence for the various treatments. There are currently no drugs approved by the Food and Drug Administration for the treatment of EoE.<\/p>\n

Key Findings<\/p>\n

This section includes a glimpse of the Eosinophilic Esophagitis market in the 7MM. The market size of Eosinophilic Esophagitis in the seven major markets was found to be USD 430.9 million in 2020.<\/p>\n

The United States: Market Outlook<\/p>\n

This section provides the total Eosinophilic Esophagitis market size and market size by therapies of Eosinophilic Esophagitis in the United States.<\/p>\n

The United States accounts for the highest market size of Eosinophilic Esophagitis in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.<\/p>\n

PPIs are useful as a first-line treatment for patients with EoE. Initial PPI doses of 20-40 mg or 1 mg\/kg per dose are given twice daily in adults and children, respectively. The reported response rates to PPI therapy in the EoE population can vary widely from 30–70%. This is likely due to distinct clinical scenarios but there are currently no clinical features that discern a patient who will respond to PPI monotherapy.<\/p>\n

Corticosteroids are another effective therapy for the treatment of EoE. The formulation of the most commonly used corticosteroids, including budesonide, fluticasone propionate, and ciclesonide, influences histological remission.<\/p>\n

Bougie and balloon dilation is the only endoscopic treatment available for EoE. It is performed in patients with persistent dysphagia resistant to medical treatment in whom remission of inflammation has been achieved and in patients with severe dysphagia and a history of food impaction.<\/p>\n

Request for sample pages @ Eosinophilic Esophagitis Market Size <\/a><\/p>\n

Table of contents<\/p>\n

1. Key Insights<\/p>\n

2. Report Introduction<\/p>\n

3. Eosinophilic Esophagitis Market Overview at a Glance<\/p>\n

3.1. Market Share (%) Distribution of Eosinophilic Esophagitis in 2018<\/p>\n

3.2. Market Share (%) Distribution of Eosinophilic Esophagitis in 2030<\/p>\n

4. Eosinophilic Esophagitis Patient Split at a Glance<\/p>\n

4.1. Patient Split (%) Distribution of Eosinophilic Esophagitis in 2018<\/p>\n

4.2. Patient Split (%) Distribution of Eosinophilic Esophagitis in 2030<\/p>\n

5. Executive Summary of Eosinophilic Esophagitis<\/p>\n

6. Disease Background and Overview<\/p>\n

6.1. Introduction<\/p>\n

6.2. Clinical Manifestation<\/p>\n

6.3. Risk factors associated with EoE<\/p>\n

6.4. Phenotypes, Endotypes and Genotype correlation in Eosinophilic Esophagitis<\/p>\n

6.5. Pathophysiology<\/p>\n

6.6. Diagnosis<\/p>\n

6.6.1. Differential Diagnosis<\/p>\n

6.6.2. Complexities in EoE Diagnosis<\/p>\n

7. Treatment<\/p>\n

8. Guidelines for Management of EoE<\/p>\n

8.1. AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis<\/p>\n

8.2. European statements and recommendations on the management of EoE<\/p>\n

9. Epidemiology and Patient Population<\/p>\n

9.1. Key Findings<\/p>\n

9.2. 7MM Total Diagnosed Prevalent Population of Eosinophilic Esophagitis<\/p>\n

9.3. Epidemiology of Eosinophilic Esophagitis<\/p>\n

9.4. The United States<\/p>\n

9.4.1. Diagnosed prevalent cases of Eosinophilic Esophagitis in the United States<\/p>\n

9.4.2. Gender-specific cases of Eosinophilic Esophagitis in the United States<\/p>\n

9.4.3. Age-specific cases of Eosinophilic Esophagitis in the United States<\/p>\n

9.5. EU5<\/p>\n

9.5.1. Germany<\/p>\n

9.5.1.1. Diagnosed prevalent cases of Eosinophilic Esophagitis in Germany<\/p>\n

9.5.1.2. Gender-specific cases of Eosinophilic Esophagitis in Germany<\/p>\n

9.5.1.3. Age-specific Cases of Eosinophilic Esophagitis in Germany<\/p>\n

9.5.2. France<\/p>\n

9.5.2.1. Diagnosed prevalent cases of Eosinophilic Esophagitis in France<\/p>\n

9.5.2.2. Gender-specific cases of Eosinophilic Esophagitis in France<\/p>\n

9.5.2.3. Age-specific Cases of Eosinophilic Esophagitis in France<\/p>\n

9.5.3. Italy<\/p>\n

9.5.3.1. Diagnosed prevalent cases of Eosinophilic Esophagitis in Italy<\/p>\n

9.5.3.2. Gender-specific cases of Eosinophilic Esophagitis in Italy<\/p>\n

9.5.3.3. Age-specific Cases of Eosinophilic Esophagitis in Italy<\/p>\n

9.5.4. Spain<\/p>\n

9.5.4.1. Diagnosed prevalent cases of Eosinophilic Esophagitis in Spain<\/p>\n

9.5.4.2. Gender-specific cases of Eosinophilic Esophagitis in Spain<\/p>\n

9.5.4.3. Age-specific Cases of Eosinophilic Esophagitis in Spain<\/p>\n

9.5.5. United Kingdom<\/p>\n

9.5.5.1. Diagnosed prevalent cases of Eosinophilic Esophagitis in the UK<\/p>\n

9.5.5.2. Gender-specific cases of Eosinophilic Esophagitis in the United Kingdom<\/p>\n

9.5.5.3. Age-specific Cases of Eosinophilic Esophagitis in the United Kingdom<\/p>\n

9.6. Japan<\/p>\n

9.6.1.1. Diagnosed prevalent cases of Eosinophilic Esophagitis in Japan<\/p>\n

9.6.1.2. Gender-specific cases of Eosinophilic Esophagitis in Japan<\/p>\n

9.6.1.3. Age-specific Cases of Eosinophilic Esophagitis in Japan<\/p>\n

10. Organizations contributing toward the fight against EoE<\/p>\n

11. Patient Journey<\/p>\n

12. Case Report<\/p>\n

13. Marketed Drug<\/p>\n

13.1. Jorveza: Dr Falk Pharma GmbH<\/p>\n

13.2. Drug Description<\/p>\n

13.3. Regulatory Milestone<\/p>\n

13.4. Safety and Efficacy<\/p>\n

13.5. Side Effect<\/p>\n

13.6. Product Profile<\/p>\n

14. Emerging Therapies<\/p>\n

14.1. Key Cross Competition<\/p>\n

14.2. Budesonide Oral Suspension: Takeda<\/p>\n

14.2.1. Drug Description<\/p>\n

14.2.2. Other Development Activities<\/p>\n

14.2.3. Clinical Development<\/p>\n

14.2.4. Clinical Trial Information<\/p>\n

14.2.5. Safety and Efficacy<\/p>\n

14.2.6. Product Profile<\/p>\n

14.3. Dupilumab: Regeneron Pharmaceuticals\/Sanofi<\/p>\n

14.3.1. Drug Description<\/p>\n

14.3.2. Other Development Activities<\/p>\n

14.3.3. Clinical Development<\/p>\n

14.3.4. Clinical Trial Information<\/p>\n

14.3.5. Safety and Efficacy<\/p>\n

14.3.6. Product Profile<\/p>\n

14.4. Cendakimab: Bristol-Myers Squibb<\/p>\n

14.4.1. Drug Description<\/p>\n

14.4.2. Other Development Activities<\/p>\n

14.4.3. Clinical Development<\/p>\n

14.4.4. Clinical Trial Information<\/p>\n

14.4.5. Safety and Efficacy<\/p>\n

14.4.6. Product Profile<\/p>\n

14.5. APT-1011: Ellodi Pharmaceuticals<\/p>\n

14.5.1. Drug Description<\/p>\n

14.5.2. Other Development Activities<\/p>\n

14.5.3. Clinical Development<\/p>\n

14.5.4. Clinical trial information<\/p>\n

14.5.5. Safety and Efficacy<\/p>\n

14.5.6. Product Profile<\/p>\n

14.6. Benralizumab: AstraZeneca<\/p>\n

14.6.1. Drug Description<\/p>\n

14.6.2. Other Development Activities<\/p>\n

14.6.3. Clinical Development<\/p>\n

14.6.4. Clinical trial information<\/p>\n

14.6.5. Product Profile<\/p>\n

14.7. Lirentelimab: Allakos<\/p>\n

14.7.1. Drug Description<\/p>\n

14.7.2. Other Development Activities<\/p>\n

14.7.3. Clinical Development<\/p>\n

14.7.4. Clinical Trial Information<\/p>\n

14.7.5. Safety and Efficacy<\/p>\n

14.7.6. Product Profile<\/p>\n

15. Other Promising Therapies<\/p>\n

15.1. ESO-101: EsoCap AG<\/p>\n

15.1.1. Drug Description<\/p>\n

15.1.2. Other Development Activities<\/p>\n

15.1.3. Clinical Development<\/p>\n

15.1.4. Clinical trial information<\/p>\n

15.1.5. Product Profile<\/p>\n

15.2. Etrasimod: Arena Pharmaceutical<\/p>\n

15.2.1. Drug Description<\/p>\n

15.2.2. Other Development Activities<\/p>\n

15.2.3. Clinical Development<\/p>\n

15.2.4. Clinical Trial Information<\/p>\n

15.2.5. Product Profile<\/p>\n

15.3. Mepolizumab: GlaxoSmithKline<\/p>\n

15.3.1. Drug Description<\/p>\n

15.3.2. Clinical Development<\/p>\n

15.3.3. Clinical Trial Information<\/p>\n

15.3.4. Product Profile<\/p>\n

16. Eosinophilic Esophagitis: 7 Major Market Analysis<\/p>\n

16.1. Key Findings<\/p>\n

16.2. Market Size of Eosinophilic Esophagitis in 7MM<\/p>\n

16.3. Market Outlook<\/p>\n

16.4. United States Market Size<\/p>\n

16.4.1. Total Market Size of Eosinophilic Esophagitis in the United States<\/p>\n

16.4.2. Market Size of Eosinophilic Esophagitis by Therapies in United States<\/p>\n

16.4.3. Market Size of Eosinophilic Esophagitis by Class in the United States<\/p>\n

16.5. EU-5 Market Size<\/p>\n

16.5.1. Germany<\/p>\n

16.5.1.1. Total Market size of Eosinophilic Esophagitis in Germany<\/p>\n

16.5.1.2. Market Size of Eosinophilic Esophagitis by Therapies in Germany<\/p>\n

16.5.1.3. Market Size of Eosinophilic Esophagitis by Class in Germany<\/p>\n

16.5.2. France<\/p>\n

16.5.2.1. Total Market size of Eosinophilic Esophagitis in France<\/p>\n

16.5.2.2. Market Size of Eosinophilic Esophagitis by Therapies in France<\/p>\n

16.5.2.3. Market Size of Eosinophilic Esophagitis by Class in France<\/p>\n

16.5.3. Italy<\/p>\n

16.5.3.1. Total Market size of Eosinophilic Esophagitis in Italy<\/p>\n

16.5.3.2. Market Size of Eosinophilic Esophagitis by Therapies in Italy<\/p>\n

16.5.3.3. Market Size of Eosinophilic Esophagitis by Class Italy<\/p>\n

16.5.4. Spain<\/p>\n

16.5.4.1. Total Market size of Eosinophilic Esophagitis in Spain<\/p>\n

16.5.4.2. Market Size of Eosinophilic Esophagitis by Therapies in Spain<\/p>\n

16.5.4.3. Market Size of Eosinophilic Esophagitis by Class in Spain<\/p>\n

16.5.5. United Kingdom<\/p>\n

16.5.5.1. Total Market size of Eosinophilic Esophagitis in United Kingdom<\/p>\n

16.5.5.2. Market Size of Eosinophilic Esophagitis by Therapies in United Kingdom<\/p>\n

16.5.5.3. Market Size of Eosinophilic Esophagitis by Class in the United Kingdom<\/p>\n

16.6. Japan<\/p>\n

16.6.1. Total Market size of Eosinophilic Esophagitis in Japan<\/p>\n

16.6.2. Market Size of Eosinophilic Esophagitis by Therapies in Japan<\/p>\n

16.6.3. Market Size of Eosinophilic Esophagitis by Class in Japan<\/p>\n

17. KOL Views<\/p>\n

18. Market Drivers<\/p>\n

19. Market Barriers<\/p>\n

20. SWOT Analysis<\/p>\n

21. Unmet Needs<\/p>\n

22. Appendix<\/p>\n

22.1. Bibliography<\/p>\n

22.2. Report Methodology<\/p>\n

23. DelveInsight Capabilities<\/p>\n

24. Disclaimer<\/p>\n

25. About DelveInsight<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight<\/a>
Contact Person:<\/strong> Priya Maurya
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 09650213330
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Albany
State:<\/strong> New York
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight Business Research LLP DelveInsight\u2019s \u2018Eosinophilic Esophagitis Market\u2019 report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of EoE in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-559031","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/559031","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=559031"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/559031\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=559031"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=559031"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=559031"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}